Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.89, read 2026-10-27
Ethical does not pass the values gate
Price118.51 USD
Fair value127.30
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markup104.68+13.2% to today ✓Accumulation gives way to Markup first Markup read since August
2026-10-02Read Accumulation108.40+9.3% to today ✓Markup gives way to Accumulation first Accumulation read since August
2026-08-31Read Markup106.60+11.2% to today ✓Accumulation gives way to Markup after a 37% rise in 4 weeks
2026-08-01Read Accumulation77.86+52.2% to today ✓Markup gives way to Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Haemonetics Corporation holds its Markup at $118.51. Consolidating, no directional conviction, held for 9 days.
As held on the ledger · 2026-10-23
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 9 days
Price at the screen
$118.51
Valuation
56.57 trailing · 20.27 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.61
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
51.11%
Below 33%
Interest-bearing debt is 51.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
19.30%
Below 49%
Money owed to the company is 19.3% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Haemonetics's business is in a permissible area, but its interest-bearing debt is about 51% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HAE's ethical verdict changes
Today HAE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 7.4% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +8% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Blood Tech Firm Lacks Spark Despite Safety Margin
Picture a hospital running low on plasma, the quiet network of machines and software that keeps supplies moving. Haemonetics sits in that chain, selling automated collection systems across plasma, blood centres and hospital wards. Revenue edges up just 5 percent a year, margins sit at 7 percent and return on equity reaches only 12 percent. The shares trade at 13.8 times forward earnings with a 34 percent gap to our fair value, yet the opportunity rating stays at none.
We pass because the numbers do not add up to anything special. Growth stays modest, profitability thin and the moat unknown. Ten analysts call the stock a buy with an $88 median target, still below our calculated worth, but nothing here suggests the business can widen its lead or lift returns enough to justify a position.
Currency swings and hospital budget cycles add real volatility. Low margins leave little room if collection volumes slow or rivals gain ground. Ethical screen clears, yet the overall picture stays unconvincing. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HAE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Markup$117.11-3.8%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 54% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
2026-10-18Markup$121.72+16.3%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
2026-10-11Markup · changed$104.68-3.4%Entry 7
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
2026-08-31Markup · changed$106.60+36.9%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 36.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
2026-07-18Markup$78.20+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
2026-07-03Markup$78.20+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$78.20Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
